sincalide · Maia Pharms Inc · NDA 210850

Sincalide

Earliest generic entry, as listed
20 Apr 2038

Blocked by patent: US 11110063, US 11318100, US 11737983.

Listed patents · 3 unexpired

9 Orange Book listing rows for 3 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 11110063drug product, use U-3481, U-3482, U-348320 Apr 2038
US 11110063 listing rowdrug product, use U-3481 · sets the listed date20 Apr 2038
US 11110063 listing rowdrug product, use U-3482 · sets the listed date20 Apr 2038
US 11110063 listing rowdrug product, use U-3483 · sets the listed date20 Apr 2038
US 11318100drug product, use U-3477, U-3478, U-3479, U-348020 Apr 2038
US 11318100 listing rowdrug product, use U-3477 · sets the listed date20 Apr 2038
US 11318100 listing rowdrug product, use U-3478 · sets the listed date20 Apr 2038
US 11318100 listing rowdrug product, use U-3479 · sets the listed date20 Apr 2038
US 11318100 listing rowdrug product, use U-3480 · sets the listed date20 Apr 2038
US 11737983drug product, use U-3482, U-368920 Apr 2038
US 11737983 listing rowdrug product, use U-3482 · sets the listed date20 Apr 2038
US 11737983 listing rowdrug product, use U-3689 · sets the listed date20 Apr 2038

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
210850 · 001 · RLDpowder, intravenous0.005MG/VIAL20 Apr 2038